ストックスクリーナーアプリを入手
1.13
4.58%
-0.06
前日終値:
$1.19
開ける：
$1.17
24時間の取引高:
29,487
Relative Volume:
0.29
時価総額：
$21.42M
収益：
$411.00K
当期純損益:
$-4.85M
株価収益率:
-2.5682
EPS:
-0.44
ネットキャッシュフロー:
$-4.88M
1週間 パフォーマンス:
-6.93%
1か月 パフォーマンス:
-19.47%
6か月 パフォーマンス:
-49.08%
1年 パフォーマンス:
-63.72%
1日の値動き範囲:
$1.11
$1.17
1週間の範囲:
$1.11
$1.24
52週間の値動き範囲:
$1.11
$4.44
Lexaria Bioscience Corp Stock (LEXX) Company Profile
名前
Lexaria Bioscience Corp
セクター
電話
250-765-6424
住所
100 - 740 MCCURDY ROAD, KELOWNA
LEXX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
1.13 | 21.42M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.39 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
611.04 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
654.99 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.23 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.12 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexaria Bioscience Corp (LEXX) 最新ニュース
Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria Bioscience announces $2M registered direct offering; shares slip 19% - MSN
Lexaria Bioscience stock hits 52-week low at $1.14 By Investing.com - Investing.com India
Lexaria Bioscience stock hits 52-week low at $1.14 - Investing.com Australia
Lexaria Announces Closing of $2 Million Registered Direct Offeri - GuruFocus
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock - Yahoo Finance
Lexaria Bioscience Secures $2 Million in Direct Stock Offering - TipRanks
Lexaria Secures $2M Strategic Investment in Clean Direct Offering Amid Market Turbulence - Stock Titan
Market Watch Highlights: Lexaria Bioscience Corp (LEXX) Ends on an Downturn Note at 1.35 - DWinneX
Lexaria Bioscience Corp (LEXX) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Lexaria Raises $2 Million in Registered Direct Offering Despite Market Challenges - citybuzz -
What is Zacks Small Cap’s Estimate for LEXX FY2025 Earnings? - Defense World
Lexaria Bioscience (LEXX) Announces $2M Direct Offering | LEXX S - GuruFocus
Lexaria Bioscience Secures $2 Million in Registered Direct Stock Offering - citybuzz -
Lexaria Announces $2 Million Registered Direct Offering of Commo - GuruFocus
Lexaria Bioscience secures $2 million in direct offering By Investing.com - Investing.com South Africa
Lexaria Bioscience secures $2 million in direct offering - Investing.com
Lexaria Announces $2 Million Registered Direct Offering of Common Stock - TradingView
Lexaria Lands $2M Strategic Investment: Institutional Investor Backs Biotech at $1.00 Per Share - Stock Titan
Lexaria Bioscience (OTCMKTS:LXRP) versus U.S. Gold (NASDAQ:USAU) Critical Comparison - Defense World
LEXX: Second Quarter Results - Yahoo Finance
Lexaria Bioscience (LEXX) Advances in GLP-1 Technology Amid Indu - GuruFocus
Recent GLP-1-Industry Developments Highlight the Promise of Lexa - GuruFocus
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology | LEXX Stock News - GuruFocus
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology - TradingView
Revolutionary Technology Could Solve GLP-1's Biggest Challenge: 64% Patient Dropout Rate - Stock Titan
Lexaria Bioscience earnings beat by $0.02, revenue topped estimates - Investing.com
Lexaria Corp. Announces Oil Discovery at PPF-12-7 well in Belmont Lake - marketscreener.com
Lifezone Metals (NYSE:LZM) vs. Lexaria Bioscience (OTCMKTS:LXRP) Financial Review - Defense World
Lexaria Bioscience Corp reports results for the quarter ended February 28Earnings Summary - TradingView
Lexaria Bioscience Corp. SEC 10-Q Report - TradingView
60,640 Shares in Lexaria Bioscience Corp. (NASDAQ:LEXX) Acquired by Raymond James Financial Inc. - Defense World
Lexaria gets ethics board okay for oral GLP-1 study - MSN
We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully - Yahoo
HighTower Advisors LLC Boosts Holdings in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria Completes Enrollment for Pioneering Drug Delivery Study - TipRanks
Lexaria completes enrollment for diabetes drug study - Investing.com
Lexaria completes enrollment for diabetes drug study By Investing.com - Investing.com UK
Lexaria's GLP-1 Study Hits Major Milestone with 20% Higher Patient Enrollment - Stock Titan
Lexaria begins human trial for oral diabetes treatment - Investing.com India
Lexaria begins human trial for oral diabetes treatment By Investing.com - Investing.com South Africa
Lexaria Bioscience Begins Human Trials for Oral Liraglutide Alternative - TipRanks
Lexaria's Human GLP-1 Study #5 Begins Dosing - TradingView
Revolutionary Oral GLP-1 Drug Challenges $1.8B Saxenda Market in New Trial - Stock Titan
Lexaria Bioscience (LEXX) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Oral tirzepatide capsules match injection efficacy in Lexaria study By Investing.com - Investing.com South Africa
Lexaria’s Oral Capsules Rival Injectable Weight Loss Treatment - TipRanks
Oral tirzepatide capsules match injection efficacy in Lexaria study - Investing.com
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R) - ACCESS Newswire
Lexaria Bioscience's (LEXX) DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound - StreetInsider.com
Lexaria Bioscience Corp (LEXX) 財務データ
収益
当期純利益
現金流量
EPS
0.58%
0.47%
大文字化:
|
ボリューム (24 時間):